Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies.

Fred PoordadNorah A TerraultNaim AlkhouriWei TianLee F AllenMordechai Rabinovitz

Published in: International journal of hepatology (2020)

These integrated analyses confirmed the superiority of avatrombopag to placebo in reducing platelet transfusions or rescue procedures for bleeding in patients with thrombocytopenia and CLD scheduled to undergo an invasive procedure, and its tolerable safety profile. Importantly, these data warrant reconsideration of clinical decision making regarding the need to treat thrombocytopenia in patients with CLD. This trial was registered with NCT01972529 and NCT01976104.

Keyphrases

decision making
phase iii
study protocol
electronic health record
big data
combination therapy
double blind
case control
placebo controlled